Skip to main content

neuronascent-logo

CLARKSVILLE, MD–(Marketwired – Apr 6, 2015) – Neuronascent, a biopharmaceutical company developing non-invasive, neuron regenerative therapeutics aimed at reversing cognitive deficits in Alzheimer’s disease, today announced the closing of a round of financing for up to $1.2 million. Neuronascent’s human neuronal progenitor-based discovery platform identified a number of novel orally-available therapeutics that promote new neuron generation at the same time inhibiting loss of neurons. Proceeds from this first institutional investment will allow the development of Neuronascent’s lead Alzheimer’s candidate, NNI-362, to the point of first-in-human clinical testing. The Company expects to complete all IND-enabling studies in 2015, with the considerable support of the National Institute of Aging’s (NIA) Alzheimer’s Disease Translational Research Program.

{iframe}http://www.marketwired.com/press-release/neuronascent-secures-financing-for-development-of-its-alzheimers-therapeutic-2006709.htm{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.